### How does it work?

#### **Course format and duration**

- Short courses are divided in several learning activities such as recorded lecture, reading, quiz, and forum that altogether run over 30 minutes to 6 hours. The learning activities can be followed according to your wish. You can start a learning activity then stop and start another one, then come back later to the one you have firstly opened.
- $\odot$  Once open, your training remains accessible until completion, and within one year.

#### Attendance and progress report

The Eu2P central office can quantify and analyse your own training attendance, workload and quiz progress per learning activity and per short course.

#### **Evaluation and award**

- When your training progress reaches 100%, you perform an online graded evaluation on your whole training content.
- O This evaluation consists in a quiz covering all your learning activities.
- O The training evaluation is successful if you reach at least a 80% good score.
- > You then receive an official Eu2P certificate for your achieved competencies.

# How does it cost?

#### Affordable prices



Eu2P supports worldwide pharmaceutical companies for their in-house training plans and provides quotes tailored to their needs in terms of content, duration and number of collaborators.

For more information, contact Dr Karine Palin: <u>eu2p.office@eu2p.org</u>

#### Powered by





# GAIN FAST AND SOLID EXPERTISE IN DRUG SAFETY

# WITH ONLINE SHORT COURSES



## Eu2P short courses catalogue

| BASICS FOR PHARMACOVIGILANCE AND PHARMACOEPIDEMIOLOGY                                   | $\bigcirc$     | $\bigcirc$ |
|---|----------------|------------|
| 1. Principles in Epidemiology   | 5 h            | 500€       |
| <ol> <li>Epidemiología para los no epidemiólogos (in spanish)</li> </ol>                | 5 h            | 500€       |
| 3. Basis in statistics  | 5 h            | 500€       |
| MEDICINES PHARMACOVIGILANCE AND REGULATORY ASPECTS                                      | $\mathfrak{O}$ | $\bigcirc$ |
| Regulations outlines  |                |            |
| 1. Pre-marketing pharmacovigilance legislation  | 2 h            | 200€       |
| 2. Post-marketing pharmacovigilance legislation   | 2 h            | 200€       |
| 3. EudraVigilance & EVMPD   | 1,5 h          | 150€       |
| 4. Development Safety Update Report (DSUR)  | 1 h            | 100€       |
| 5. International Harmonisation Initiatives  | 0,5 h          | ⑪          |
| <ol> <li>Guidelines for Good Pharmacoepidemiology Practices</li> </ol>                  | 6 h            | 500€       |
| 7. Vaccines biologics regulations   | 1 h            | 100€       |
| 8. Materiovigilance regulations   | 1 h            | 100€       |
| 9. Contractual Agreements in PV   | 1,5 h          | 150€       |
| International regulations   |                |            |
| 10. US regulations  | 2 h            | 200€       |
| 11. Japanese regulations  | 2 h            | 200€       |
| 12. French regulations (in French)  | 2 h            | 200€       |
| 13. Canadian regulations  | 2 h            | 200€       |
| European Union regulations  |                |            |
| 14. GVP Module I - Pharmacovigilance V Quality Management System                        | 4 h            | 400€       |
| 15. GVP Module II - Pharmacovigilance System Master File (PSMF)                         | 2 h            | 200€       |
| 16. GVP Module III - Pharmacovigilance Inspections                                      | 1 h            | 100€       |
| 17. GVP Module IV - Pharmacovigilance Audits  | 2 h            | 200€       |
| 18. GVP Module V - Risk Management System   | 2 h            | 200€       |
| 19. GVP Module VI - Management and Reporting of Adverse Reactions to Medicinal Products | 4 h            | 400€       |
| 20. GVP Module VII - Periodic Safety Update Report (PSUR)                               | 3 h            | 300€       |
| 21. GVP Module VIII - Post-Authorisation Safety Studies (PASS)                          | 4 h            | 400€       |
| 22. GVP Module IX - Signal Management   | 1 h            | 100€       |
| 23. GVP Module XVI - Risk Minimisation Measures   | 3 h            | 300€<br>∞  |
| 24. Validation of Computerized systems  | 1 h            | ŤŤ         |
| Pharmacovigilance in practice   |                |            |
| 25. Signal detection  | 1,5 h          | 150€       |
| 26. Management and reporting of Adverse Drug Reactions (ADR)                            | 4 h            | 400€       |
| 27. Gestión y Notificación de RAM (in spanish)  | 4 h            | 400€       |
| 28. Risk Management Plans (RMP) and European Union regulatory perspective               | 2 h            | 200€       |
| 29. Principles of labeling and Summary of Product Characteristics (SmPC)                | 3 h            | 300€       |

**30**. Role of the Qualified Person responsible for Pharmacovigilance (QPPV)

|  | $\heartsuit$   |  |
|--|--|--|
| <ol> <li>Heterogeneity of treatment effect in clinical trials</li> </ol>   | 2 h  |  |
| 2. Selecting outcomes: Surrogate endpoints   | 2 h  |  |
| 3. Fundamentals of the adaptative clinical trials  | 2 h  |  |
| <ol> <li>Fundamentals of the network meta-analysis</li> </ol>  | 2 h  |  |
| 5. Composite outcomes in clinical trials   | 2 h  |  |
| 6. Early stopping rules in clinical trials   | 2 h  |  |
| 7. Non inferiority approach in clinical trials   | 2 h  |  |
| 8. Recruitement strategies in clinical trials  | 2 h  |  |
| MEDICINES RISK IDENTIFICATION AND QUANTIFICATION   | $\mathfrak{O}$   |  |
| 1. Introduction to risk management plan (RPM)  | 1 h  |  |
| 2. Concepts in risk management   | 3 h  |  |
| 3. Pharmacovigilance plan versus risk minimisation plans   | 3 h  |  |
| <ol> <li>Organisation for risk management in the industry</li> </ol>   | 3 h  |  |
| 5. Methods and new initiatives for signals detection   | 6 h  |  |
| MEDICINES BENEFIT-RISK ASSESSMENT  | $\bigcirc$   |  |
| 1. Role of benefit-risk assessment & pharmacoeconomics in decision-making of medicines   | 1 h  |  |
| 2. Principles and methods of benefit-risk assessment in decision-making of medicines   | 2 h  |  |
| 3. Drug life cycle as a tool in drug policy analysis   | 1 h  |  |
| 4. Main challenges of health economics and outcomes research   | 2 h  |  |
| MEDICINES AND PUBLIC HEALTH  | $\bigcirc$   |  |
| 1. Health care records from large databases as a tool to study the use of medicines  | 2 h  |  |
|  | 2 h  |  |
|  | 2 h  |  |
|  | 2 h  |  |
| 4. From individual cases to the community impact of adverse drug reactions: limitations  | 2 h  |  |
| · · · · · · · · · · · · · · · · · · ·  |  |  |
| 5. Drug interaction risks: the value of concomitant medication   | 2 h  |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> </ul>   | 2 h  |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> </ul>   |  |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> </ul>   | $\bigcirc$   |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> </ul>  | ()<br>2 h  |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> </ul>   | ©<br>2 h<br>2 h  |  |
| <ul> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> <li>4. Concept of risk communication throughout modern time</li> </ul>  | <ul> <li>2 h</li> <li>2 h</li> <li>1 h</li> </ul>  |  |
| <ol> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> <li>4. Concept of risk communication throughout modern time</li> <li>5. How do risk perception and risk communication hang together</li> </ol>  | <ul> <li>2 h</li> <li>2 h</li> <li>1 h</li> <li>2 h</li> </ul>                           |  |
| <ol> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> <li>4. Concept of risk communication throughout modern time</li> <li>5. How do risk perception and risk communication hang together</li> <li>6. Risk perception. How to deal with it in risk communication?</li> </ol>  | 2 h 2 h 1 h 2 h 2 h  |  |
| <ol> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION         <ol> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> <li>4. Concept of risk communication throughout modern time</li> <li>5. How do risk perception and risk communication hang together</li> <li>6. Risk perception. How to deal with it in risk communication?</li> <li>7. Communicating emerging safety risks of marketed medicines</li> </ol> </li> </ol>                                      | <ul> <li>2 h</li> <li>2 h</li> <li>1 h</li> <li>2 h</li> <li>2 h</li> <li>2 h</li> </ul> |  |
| <ol> <li>5. Drug interaction risks: the value of concomitant medication</li> <li>6. Drug misuses risks: the effects of inappropriate use of the target medicine</li> <li>MEDICINES RISK COMMUNICATION</li> <li>1. Basis of risk communication with special focus on risk communication on medicines</li> <li>2. Understand communication challenges facing the regulatory agencies</li> <li>3. How can risk communication be minimized?</li> <li>4. Concept of risk communication throughout modern time</li> <li>5. How do risk perception and risk communication hang together</li> <li>6. Risk perception. How to deal with it in risk communication?</li> <li>7. Communicating emerging safety risks of marketed medicines</li> <li>8. A case study: the pandemic influenza vaccine</li> </ol> | 2 h 2 h 1 h 2 h 2 h 2 h 2 h 1 h 1 h  |  |



3h **300€** 



